Detalles de la búsqueda
1.
A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study.
Oncologist
; 27(11): 903-e834, 2022 11 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36181763
2.
Phase II Study of S-1 and Paclitaxel Combination Therapy in Patients with Previously Treated Non-Small Cell Lung Cancer.
Oncologist
; 24(8): 1033-e617, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31040252
3.
A Phase II Study of S-1 and Paclitaxel Combination Therapy as a First-Line Treatment in Elderly Patients with Advanced Non-Small Cell Lung Cancer.
Oncologist
; 24(4): 459-e131, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30578309
4.
Phase I study of S-1 plus paclitaxel combination therapy as a first-line treatment in elderly patients with advanced non-small cell lung cancer.
Invest New Drugs
; 37(2): 291-296, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30121935
5.
Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50.
Front Immunol
; 15: 1348034, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38464519
6.
Clinical Efficacy and Safety of First- or Second-Generation EGFR-TKIs after Osimertinib Resistance for EGFR Mutated Lung Cancer: A Prospective Exploratory Study.
Target Oncol
; 18(5): 657-665, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37610516
7.
Early Tumor Shrinkage as a Predictor of Favorable Treatment Outcomes in Patients With Extensive-Stage SCLC Who Received Programmed Cell Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy: A Prospective Observational Study.
JTO Clin Res Rep
; 4(4): 100493, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-37025120
8.
Prospective Observational Study Evaluating the Prognostic Value of the G8 Screening Tool for Extensive-Stage Small Cell Lung Cancer Patients Who Received Programmed Death-Ligand 1 Inhibitor plus Platinum-Etoposide Chemotherapy.
Drugs Aging
; 40(6): 563-571, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37145245
9.
Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
JAMA Netw Open
; 6(7): e2322915, 2023 07 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37432682
10.
Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status.
Target Oncol
; 18(6): 915-925, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37902896
11.
Efficacy and Safety of Programmed Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC: A Prospective Observational Study.
JTO Clin Res Rep
; 3(7): 100353, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35789793
12.
[A case of microscopic polyangiitis with silicosis].
Nihon Kokyuki Gakkai Zasshi
; 49(9): 636-41, 2011 Sep.
Artículo
en Japonés
| MEDLINE | ID: mdl-22073607
13.
[Case of thymic carcinoid accompanied by adenocarcinoma of the lung].
Nihon Kokyuki Gakkai Zasshi
; 48(12): 950-4, 2010 Dec.
Artículo
en Japonés
| MEDLINE | ID: mdl-21226303
14.
Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients.
Transl Lung Cancer Res
; 8(4): 450-460, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31555518
15.
Feasibility Study of Sequentially Alternating EGFR-TKIs and Chemotherapy for Patients with Non-small Cell Lung Cancer.
Anticancer Res
; 38(4): 2385-2390, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29599365
Resultados
1 -
15
de 15
1
Próxima >
>>